Retatrutide, a novel dual-acting glucose-responsive incretin agent, represents a significant progression in peptide treatments for the management of type 2 diabetic conditions and, increasingly, excess adiposity. Unlike many existing medicinal interventions, retatrutide integrates the actions of a GLP-1 receptor agonist and a GIP receptor agonist,